Renaissance Technologies LLC Purchases 2,085,972 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Renaissance Technologies LLC boosted its position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 1,058.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,283,072 shares of the company's stock after acquiring an additional 2,085,972 shares during the period. Renaissance Technologies LLC owned 1.04% of Lineage Cell Therapeutics worth $1,147,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Fort Sheridan Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock worth $28,000 after acquiring an additional 23,000 shares during the last quarter. HighTower Advisors LLC boosted its stake in Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock worth $29,000 after buying an additional 19,100 shares in the last quarter. Atria Wealth Solutions Inc. bought a new position in Lineage Cell Therapeutics during the fourth quarter valued at approximately $29,000. SG Americas Securities LLC raised its stake in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock worth $35,000 after acquiring an additional 18,053 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Lineage Cell Therapeutics by 33.0% in the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company's stock worth $48,000 after acquiring an additional 23,527 shares during the last quarter. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Trading Down 3.4 %

LCTX stock traded down $0.02 during midday trading on Monday, reaching $0.47. 49,541 shares of the company's stock traded hands, compared to its average volume of 1,605,903. The stock's 50-day moving average is $0.49 and its 200 day moving average is $0.64. The stock has a market cap of $104.48 million, a P/E ratio of -3.95 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 52-week low of $0.37 and a 52-week high of $1.40.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. D. Boral Capital reissued a "buy" rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. B. Riley cut their target price on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, March 14th. Finally, Maxim Group dropped their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating for the company in a report on Friday, January 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $4.20.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.